发明名称 Use of gaba, inverse agonists in combination with nicotine receptor partial agonist, estrogen, selective estrogen modulators, or vitamin E for the treatment of cognitive disorders
摘要 A pharmaceutical composition and method of treatment of diseases of cognitive dysfunction in a mammal comprising administration of a GABAA inverse agonist or a pharmaceutically acceptable salt thereof; and a nicotine receptor partial agonist, an estrogenic agent, selective estrogen receptor modulator or vitamin E or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier. The GABAA inverse agonist, and nicotine receptor partial agonist, estrogen, selective estrogen receptor modulator or vitamin E are present in amounts that render the composition effective enhancing cognition or in the treatment of diseases of cognitive dysfunction including but not limited to Alzheimer's Disease (AD), mild cognitive impairment, age-related cognitive decline, vascular dementia, Parkinson's disease, Huntington's disease, memory impairment associated with depresssion or anxiety, schizophrenia, Down's syndrome, stroke, traumatic brain injury (TBI), AIDS associated dementia and attention deficit disorder. The method of using these compositions is also disclosed.
申请公布号 US2004082555(A1) 申请公布日期 2004.04.29
申请号 US20030727934 申请日期 2003.12.02
申请人 PFIZER INC 发明人 VILLALOBOS ANABELLA
分类号 C07D221/22;A61K31/00;A61K31/195;A61K31/355;A61K31/4353;A61K31/4375;A61K31/439;A61K31/4985;A61K31/56;A61K31/565;A61K45/00;A61K45/06;A61P9/10;A61P25/00;A61P25/02;A61P25/14;A61P25/16;A61P25/22;A61P25/24;A61P25/28;A61P31/18;A61P43/00;C07D471/04;C07D471/08;C07D498/08;C07D513/08;(IPC1-7):A61K31/56 主分类号 C07D221/22
代理机构 代理人
主权项
地址
您可能感兴趣的专利